Fructose-1,6-bisphosphatase: Genetic and physical mapping to human chromosome 9q22.3 and evaluation in non-insulin-dependent diabetes mellitus

Journal Article · Fri Sep 01 00:00:00 EDT 1995 · Genomics

DOI:https://doi.org/10.1006/geno.1995.1230· OSTI ID:433300

Rothschild, C B; Akots, G; Roh, B ^[1]

---

1. Wake Forest Univ., Winston-Salem, NC (United States); and others

PCR primers specific to the human liver fructose-1,6-bisphosphatase (FBP) gene were designed and used to isolate a cosmid clone. Physical mapping of the FBP cosmid by FISH, and genetic mapping of an associated GA repeat polymorphism (PIC = 0.35), located the liver FBP gene to chromosome 9q22.3 with no recombination between FBP and the index markers D9S196 (Z{sub max} = 13.2), D9S280 (Z{sub max} = 11.7), D9S287 (Z{sub max} = 15.6), and D9S176 (Z{sub max} = 14.4). Amplification using FBP exon-specific primers with a YAC contig from this region of chromosome 9 further refined the placement of FBP genomic sequences to an approximately 1.7-cM region flanked by D9S280 and D9S287, near the gene for Fanconi anemia group C. Precise localization of the FBP gene enabled evaluation of FBP as a candidate gene for maturity-onset diabetes of the young (MODY) and non-insulin-dependent diabetes (NIDDM) in both Caucasian and African-American families, using the highly informative markers D9S287 and D9S176. Although FBP is a rate-limiting enzyme in gluconeogenesis, using both parametric and nonparametric analysis there was no evidence for linkage of FBP to diabetes in these families. 30 refs., 4 figs., 2 tabs.

• OSTI ID: 433300
• Journal Information: Genomics, Vol. 29, Issue 1; Other Information: PBD: 1 Sep 1995
• Country of Publication: United States
• Language: English

Related Subjects

55 BIOLOGY AND MEDICINE
BASIC STUDIES
HUMAN CHROMOSOME 9
GENETIC MAPPING
L CODES
PHOSPHATASES
GENE REGULATION
DNA SEQUENCING
DNA-CLONING
GENE MUTATIONS
METABOLIC DISEASES
GENETICS
GLUCOSE
BIOSYNTHESIS
GENES
BIOLOGICAL MARKERS
POLYMERASE CHAIN REACTION
FRUCTOSE
DNA HYBRIDIZATION
GENE AMPLIFICATION
PATIENTS
INSULIN
COSMIDS